JP2016536327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536327A5 JP2016536327A5 JP2016537322A JP2016537322A JP2016536327A5 JP 2016536327 A5 JP2016536327 A5 JP 2016536327A5 JP 2016537322 A JP2016537322 A JP 2016537322A JP 2016537322 A JP2016537322 A JP 2016537322A JP 2016536327 A5 JP2016536327 A5 JP 2016536327A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- functional fragment
- neutralizing antibody
- days
- csf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003472 neutralizing effect Effects 0.000 claims 59
- 239000012634 fragment Substances 0.000 claims 52
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 29
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 29
- 241000288906 Primates Species 0.000 claims 28
- 208000027866 inflammatory disease Diseases 0.000 claims 21
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 19
- 229960000485 methotrexate Drugs 0.000 claims 19
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 201000008482 osteoarthritis Diseases 0.000 claims 12
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 11
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 9
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 9
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 6
- 230000003432 anti-folate effect Effects 0.000 claims 6
- 229940127074 antifolate Drugs 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 230000009266 disease activity Effects 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000004052 folic acid antagonist Substances 0.000 claims 6
- 229960000074 biopharmaceutical Drugs 0.000 claims 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims 3
- 230000004968 inflammatory condition Effects 0.000 claims 3
- 208000004235 neutropenia Diseases 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 2
- 206010033661 Pancytopenia Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 2
- 208000024389 cytopenia Diseases 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 2
- 229960004171 hydroxychloroquine Drugs 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 2
- 229960000681 leflunomide Drugs 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 2
- 229960001940 sulfasalazine Drugs 0.000 claims 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 206010065553 Bone marrow failure Diseases 0.000 claims 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 claims 1
- 206010071602 Genetic polymorphism Diseases 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 claims 1
- 108010007666 IMP cyclohydrolase Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 claims 1
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 108010045040 Phosphoribosylaminoimidazolecarboxamide formyltransferase Proteins 0.000 claims 1
- 101150006379 Rfc1 gene Proteins 0.000 claims 1
- 108010022394 Threonine synthase Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims 1
- 230000003092 anti-cytokine Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 230000001185 psoriatic effect Effects 0.000 claims 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361871900P | 2013-08-30 | 2013-08-30 | |
| US201361871904P | 2013-08-30 | 2013-08-30 | |
| US61/871,904 | 2013-08-30 | ||
| US61/871,900 | 2013-08-30 | ||
| PCT/EP2014/068489 WO2015028657A1 (en) | 2013-08-30 | 2014-09-01 | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020042267A Division JP2020109108A (ja) | 2013-08-30 | 2020-03-11 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016536327A JP2016536327A (ja) | 2016-11-24 |
| JP2016536327A5 true JP2016536327A5 (enExample) | 2017-10-12 |
Family
ID=51454704
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537322A Pending JP2016536327A (ja) | 2013-08-30 | 2014-09-01 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ |
| JP2020042267A Pending JP2020109108A (ja) | 2013-08-30 | 2020-03-11 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ |
| JP2022076303A Pending JP2022105160A (ja) | 2013-08-30 | 2022-05-02 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ |
| JP2024103720A Pending JP2024123249A (ja) | 2013-08-30 | 2024-06-27 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020042267A Pending JP2020109108A (ja) | 2013-08-30 | 2020-03-11 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ |
| JP2022076303A Pending JP2022105160A (ja) | 2013-08-30 | 2022-05-02 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ |
| JP2024103720A Pending JP2024123249A (ja) | 2013-08-30 | 2024-06-27 | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10745475B2 (enExample) |
| EP (2) | EP3889178A1 (enExample) |
| JP (4) | JP2016536327A (enExample) |
| KR (3) | KR20160044035A (enExample) |
| CN (2) | CN105705518A (enExample) |
| AU (3) | AU2014314053C1 (enExample) |
| BR (1) | BR112016003293A8 (enExample) |
| CA (1) | CA2922251C (enExample) |
| ES (1) | ES2860480T3 (enExample) |
| MX (2) | MX385854B (enExample) |
| RU (1) | RU2714919C2 (enExample) |
| WO (1) | WO2015028657A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2575563T3 (es) | 2003-05-15 | 2016-06-29 | Ampio Pharmaceuticals, Inc. | Tratamiento de enfermedades mediadas por los linfocitos T |
| SG10201608103YA (en) | 2011-10-10 | 2016-11-29 | Ampio Pharmaceuticals Inc | Treatment of degenerative joint disease |
| EP3183240A4 (en) | 2014-08-18 | 2018-06-27 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
| HK1246669A1 (zh) | 2015-06-22 | 2018-09-14 | Ampio Pharmaceuticals, Inc. | 人血清白蛋白低分子量组分在疾病治疗中的应用 |
| CN107840885B (zh) * | 2016-09-19 | 2020-11-10 | 天境生物科技(上海)有限公司 | Gm-csf抗体及其用途 |
| MX2019003019A (es) * | 2016-09-19 | 2019-09-19 | I Mab | Anticuerpos anti-gm-csf y usos de los mismos. |
| SG10201912128SA (en) | 2017-02-01 | 2020-02-27 | Univ Yale | Treatment of diuretic resistance |
| WO2019136312A1 (en) | 2018-01-05 | 2019-07-11 | Corvidia Therapeutics, Inc. | Methods for treating il-6 mediated inflammation without immunosuppression |
| SG11202008934PA (en) * | 2018-03-14 | 2020-10-29 | Univ Indiana Res & Tech Corp | Precision medicine for pain: diagnostic biomarkers, pharmacogenomics, and repurposed drugs |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
| US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
| JPS59147297A (ja) | 1983-02-10 | 1984-08-23 | 株式会社日立製作所 | 原子炉圧力容器の耐震構造 |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0158487B1 (en) | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stable composition of interleukin-2 |
| GB8624899D0 (en) | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5070013A (en) | 1988-05-31 | 1991-12-03 | Schering Corporation | Immunochemical assay for human granulocyte-macrophage colony stimulating factor |
| GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| WO1994009149A1 (en) | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| CA2060741A1 (en) | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| US6309636B1 (en) | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| DK2275119T3 (da) | 1995-07-27 | 2013-11-11 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| NZ507381A (en) | 1998-04-21 | 2003-12-19 | Micromet Ag | CD19xCD3 specific polypeptides and uses thereof |
| AU2001232267A1 (en) | 2000-02-14 | 2001-08-20 | Japan As Represented By Director General Of Agency Of National Institute Of Infectious Deseases | Remedies for hepatitis c |
| US20050271663A1 (en) | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| EP1409018B1 (en) | 2001-07-25 | 2010-01-06 | Facet Biotech Corporation | Stable lyophilized pharmaceutical formulation the igg antibody daclizumab |
| CN1292655C (zh) | 2001-11-08 | 2007-01-03 | 蛋白质设计实验室股份有限公司 | IgG抗体稳定的液态药物制剂 |
| WO2003068924A2 (en) | 2002-02-13 | 2003-08-21 | Ludwig Institute For Cancer Research | Fusion proteins of humanized g250 specific antibodies and uses thereof |
| WO2003072060A2 (en) | 2002-02-27 | 2003-09-04 | Immunex Corporation | Polypeptide formulation |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| DK1576011T3 (da) | 2002-10-30 | 2009-11-30 | Genentech Inc | Inhibering af IL-17 produktion |
| AU2005249360B2 (en) | 2004-04-12 | 2011-07-21 | Medimmune, Llc | Anti-IL-9 antibody formulations and uses thereof |
| DE602004021773D1 (de) | 2004-05-05 | 2009-08-13 | Micromet Ag | Herstellung eines einkettigen fv Antikörperfragments |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| BRPI0517202A (pt) | 2004-12-16 | 2008-09-30 | Genentech Inc | método de tratamento de um distúrbio autoimune, uso de um agonista de tccr, métodos para aumentar a expressão de il-10 e de socs3 em linfócitos, método para a seleção de agonistas tccr, anticorpo monoclonal, linhagem celular de hibridoma, métodos de tratamento ou supressão de uma resposta imune e método de inibição da produção de il-17, il-6 ou gm-csf |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| ES2545769T3 (es) * | 2005-04-18 | 2015-09-15 | Amgen Research (Munich) Gmbh | Anticuerpos neutralizantes del factor estimulante de colonias de granulocitos y macrófagos humano |
| RS53743B1 (sr) | 2005-05-18 | 2015-06-30 | Morphosys Ag | Anti-gm-csf antitela i njihova upotreba |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| AU2007212147A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| ES2609088T3 (es) | 2006-02-08 | 2017-04-18 | Morphotek, Inc. | Péptidos GM-CSF antigénicos y anticuerpos anti-GM-CSF |
| RU2495050C2 (ru) | 2006-03-27 | 2013-10-10 | Медимьюн Лимитед | Связующий элемент для рецептора gm-csf |
| CN105435223A (zh) | 2006-11-21 | 2016-03-30 | 卡罗拜奥斯制药公司 | 使用gm-csf拮抗剂治疗慢性炎症疾病的方法 |
| AU2008269086B2 (en) | 2007-06-25 | 2014-06-12 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| RU2517596C2 (ru) | 2007-11-13 | 2014-05-27 | Эвек Инк. | МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С hGM-CSF, И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ |
| DK2280732T3 (en) | 2008-04-28 | 2019-01-28 | Humanigen Inc | ANTIBODIES AGAINST GRANULOCYT MACROPHAG COLONY STIMULATING FACTOR |
| CA2717987C (en) | 2008-04-29 | 2018-11-13 | Micromet Ag | Inhibitors of gm-csf and il-17 for therapy |
| ES2978209T3 (es) | 2008-12-22 | 2024-09-09 | Univ Melbourne | Tratamiento del dolor |
| CN102439039A (zh) | 2009-05-05 | 2012-05-02 | 莫佛塞斯公司 | 多发性硬化的治疗 |
| EP2458990B1 (en) | 2009-07-28 | 2016-03-30 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| WO2011080209A2 (en) | 2009-12-29 | 2011-07-07 | F. Hoffmann-La Roche Ag | Novel antibody formulation |
| CN107693791B (zh) | 2010-02-26 | 2022-06-07 | 诺沃—诺迪斯克有限公司 | 包含稳定抗体的组合物 |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| WO2013053767A1 (en) * | 2011-10-10 | 2013-04-18 | Medimmune Limited | Treatment for rheumatoid arthritis |
| SG10201803778PA (en) | 2012-09-20 | 2018-06-28 | Morphosys Ag | Treatment for rheumatoid arthritis |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| JP6339578B2 (ja) * | 2012-10-31 | 2018-06-06 | タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ | Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤 |
| CN109562493B (zh) | 2016-08-03 | 2021-10-26 | 古河电气工业株式会社 | 含金属粒子的组合物 |
-
2014
- 2014-09-01 BR BR112016003293A patent/BR112016003293A8/pt not_active Application Discontinuation
- 2014-09-01 MX MX2016002177A patent/MX385854B/es unknown
- 2014-09-01 EP EP21161450.8A patent/EP3889178A1/en active Pending
- 2014-09-01 CN CN201480047403.XA patent/CN105705518A/zh active Pending
- 2014-09-01 KR KR1020167007575A patent/KR20160044035A/ko not_active Ceased
- 2014-09-01 KR KR1020227010431A patent/KR20220045064A/ko not_active Ceased
- 2014-09-01 WO PCT/EP2014/068489 patent/WO2015028657A1/en not_active Ceased
- 2014-09-01 JP JP2016537322A patent/JP2016536327A/ja active Pending
- 2014-09-01 ES ES14758384T patent/ES2860480T3/es active Active
- 2014-09-01 US US14/913,578 patent/US10745475B2/en active Active
- 2014-09-01 RU RU2016109944A patent/RU2714919C2/ru active
- 2014-09-01 AU AU2014314053A patent/AU2014314053C1/en active Active
- 2014-09-01 CA CA2922251A patent/CA2922251C/en active Active
- 2014-09-01 EP EP14758384.3A patent/EP3039039B1/en active Active
- 2014-09-01 CN CN202410511905.9A patent/CN118178647A/zh active Pending
- 2014-09-01 KR KR1020247017478A patent/KR20240090993A/ko active Pending
-
2016
- 2016-02-18 MX MX2021010472A patent/MX2021010472A/es unknown
-
2020
- 2020-03-11 JP JP2020042267A patent/JP2020109108A/ja active Pending
- 2020-06-12 AU AU2020203917A patent/AU2020203917A1/en not_active Abandoned
- 2020-08-17 US US16/995,617 patent/US11795216B2/en active Active
-
2022
- 2022-05-02 JP JP2022076303A patent/JP2022105160A/ja active Pending
-
2023
- 2023-08-04 AU AU2023210647A patent/AU2023210647A1/en active Pending
-
2024
- 2024-06-27 JP JP2024103720A patent/JP2024123249A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016536327A5 (enExample) | ||
| Genovese et al. | Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study | |
| Behrens et al. | MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial | |
| RU2016109944A (ru) | Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков | |
| Lequerré et al. | Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France | |
| JP6657089B2 (ja) | 関節リウマチを治療するための組成物およびこれを使用する方法 | |
| Lopalco et al. | Canakinumab efficacy in refractory adult-onset PFAPA syndrome. | |
| AU2015313827C1 (en) | Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients | |
| JP2018515493A5 (enExample) | ||
| Díaz-Borjón | Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis | |
| CN1229113C (zh) | 用于治疗自身免疫性疾病的药物组合物 | |
| Bargagli et al. | Cytokine modulators in the treatment of sarcoidosis | |
| WO2003063844A2 (en) | Treatment of rheumatoid arthritis using imatinie | |
| Leng et al. | Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: a phase Ia randomized placebo-controlled study | |
| HK40062612A (en) | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics | |
| Chaplin et al. | P132 Redefining refractory disease in RA and adult polyarticular JIA: a Delphi consensus study | |
| Mallol | Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis | |
| Combe et al. | Double-blind comparison of Etanercept and Sulphasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving Sulphasalazine | |
| AU2007201056B2 (en) | Treatment of rheumatoid arthritis using imatinib | |
| Mease et al. | IL-17 inhibition in spondyloarthritis: a targeted approach in psoriatic arthritis | |
| Kavanaugh et al. | No Effect of Baseline Serum CRP Levels on Clinical Efficacy Parameters in Rheumatoid Arthritis Patients Treated with Filgotinib: Post Hoc Analysis from Two Phase 2B Studies | |
| van Vollenhoven | Cytokine inhibitors | |
| Goutet-Postel et al. | on April 8, 2016-Published by | |
| Islam et al. | Biological therapy for Rheumatoid Arthritis an update | |
| AU2003206783A1 (en) | Treatment of rheumatoid arthritis using imatinie |